Circadian molecular clocks and cancer

Kelleher, Fergal C.; Rao, Aparna D.; Maguire, Anne

doi:10.1016/j.canlet.2013.09.040

Cited by 234 publications

(202 citation statements)

References 128 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…A natural molecule secreted by the pineal gland especially nighttime, melatonin (N-acetyl-5-methoxy tryptamine) serves as a bio-clock regulator of an array of physiological functions (Kelleher et al, 2014) and displays almost null toxicity (Flo et al, 2016). Melatonin has paracrine, autocrine as well as antioxidant effects, and exerts diverse receptor-dependent and receptor-independent actions, with overall homeostatic functions and pleiotropic effects relevant to cell protection and survival (Srinivasan et al, 2008;Luchetti et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer

et al. 2017

View full text Add to dashboard Cite

Melatonin, a pineal gland hormone, exerts oncostatic activity in several types of human cancer, including prostate, the most common neoplasia and the third most frequent cause of male cancer death in the developed world. The growth of androgen-sensitive LNCaP prostate cancer cells in mice is inhibited by 3 mg/kg/week melatonin (0.09 mg/mouse/week) delivered by i.p. injections, which is equivalent to a dose of 210 mg/week in humans. The aim of this study is to test an alternative noninvasive delivery route based on transdermal administration of melatonin onto the tumor area followed by cryopass-laser treatment. Two groups of immunodepressed mice were studied, one (n ¼ 10) subjected to 18 cryopass-laser therapy sessions and one (n ¼ 10) subjected to the same treatment without melatonin. These groups were compared with mice treated with i.p.-administered melatonin or vehicle with the same time schedule. We found that cryopass-laser treatment is as efficient as i.p. injections in reducing the growth of LNCaP tumor cells, affecting plasma melatonin and redox balance. Furthermore, both delivery routes share the same effects on the involved biochemical pathway driven by hypoxia-inducible factor 1a. However, cryopass-laser, as used in the present experimental setup, is less efficient than i.p delivery route in increasing the melatonin content and Nrf2 expression in the tumor mass. We conclude that cryopass-laser treatment may have impact for melatonin-based therapy of prostate cancer, by delivering drugs transdermally without causing pain and targeting directly on the site of interest, thereby potentially making long-term treatments more sustainable.ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Thus, it is not surprising that deregulation of the circadian clock may lead to deregulation of the cell cycle control, which is one of the major hallmarks of cancer cells. 2,23 There is little known to date about molecular clock functions in melanoma, which is the most malignant form of skin cancers. A deeper and more complete understanding of circadian rhythm deregulation in melanoma patients may provide novel insights into disease predisposition and pathogenesis.…”

Section: Discussionmentioning

confidence: 99%

A polymorphic GGC repeat in the NPAS2 gene and its association with melanoma

Franzoni

Markova-Car

Pavlić

et al. 2017

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

This report describes a variable microsatellite repeat sequence located in the 5 0 untranslated exon of NSPAS2, a gene encoding a clock transcription factor. Significantly, this study is the first to show that a variant copy number GGC repeat sequence in the NPAS2 clock gene associates with melanoma risk and which may be useful in the assessment of melanoma predisposition. AbstractCircadian clock regulation in mammals is controlled by feedback loops of a set of circadian genes. One of these circadian genes, NPAS2, encodes for a member of the bHLH-PAS class of transcription factors and is expressed in the forebrain and in some peripheral organs such as liver and skin. Other biological processes are also regulated by circadian genes. For example, NPAS2 is involved in cell proliferation, DNA damage repair and malignant transformation. Aberrant expression of clock genes has been previously observed in melanoma which led to our effort to sequence the NPAS2 promoter region in this cancer type. The NPAS2 putative promoter and 5 0 untranslated region of ninety-three melanoma patients and ninety-six control subjects were sequenced and several variants were identified. Among these is a novel microsatellite comprising a GGC repeat with different alleles ranging from 7 to 13 repeats located in the 5 0 untranslated exon. Homozygosity of an allele with nine repeats (9/9) was more prevalent in melanoma than in control subjects (22.6% and 13.5%, respectively, P: 0.0206) suggesting that some NPAS2 variants might contribute to melanoma susceptibility.

show abstract

“…Mice with mutations in Cry1 or Cry2 are arrhythmic (lack a circadian rhythm) and have a faster rate of growth of implanted tumors [ 99 ]. Epidemiologically, recent data suggest a correlation between cancer and disruption of circadian rhythm as "The Nurses' Health Study" identifi ed that women working rotational night shifts have an increased incidence of breast cancer [ 100 ].…”

Section: Fbxl10mentioning

confidence: 98%

The Role of FBXL Subfamily of F-box Proteins in Tumorigenesis

North

Liu

Inuzuka

et al. 2014

SCF and APC E3 Ubiquitin Ligases in Tumorigenesis

View full text Add to dashboard Cite

The FBXL subfamily is composed of 22 members including the well-characterized FBXL1 (also known as Skp2) and FBXL2 to FBXL21, each containing an F-box motif and a C-terminal Leu-rich repeat (LRR) domain ( Fig. 3.1). Intensive studies have revealed an oncogenic role for Skp2, but the potential roles of other FBXL subfamily members in tumorigenesis have just begun to be appreciated. In this chapter, we primarily focus on summarizing the recent genetic, pathological as well as the biochemical evidence pinpointing a possible tumor suppressor or oncogenic role for each of the FBXL subfamily member proteins. In the following paragraphs, we discuss current advances in three major categories, including the physiological (mouse modeling), pathological (human clinical cancer relevance), and biochemical evidence (updated ubiquitin substrates). These three experimental evidence categories will provide insights to facilitate our understanding for their roles in tumorigenesis (Table 3.4). As stated in previous chapters, given the fact that physiological evidence (mouse modeling results) is considered as the strongest supportive data to implicate any given F-box protein in tumorigenesis (Tables 3.2 and 3.3), we choose to summarize FBXL members with available mouse genetic models.

show abstract

Circadian molecular clocks and cancer

Cited by 234 publications

References 128 publications

Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer

Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer

A polymorphic GGC repeat in the NPAS2 gene and its association with melanoma

The Role of FBXL Subfamily of F-box Proteins in Tumorigenesis

Contact Info

Product

Resources

About